Arshia Bhardwaj; Arshdeep Singh; Riya Sharma; Gopal Bhardwaj; Liza Joshi; Ramit Mahajan; Dharmatma Singh; Pankaj Kumar; Marla C. Dubinsky; Shaji Sebastian; Vandana Midha; Ajit Sood

doi:10.5217/ir.2025.00088

Articles

Page Path: HOME > Intest Res > Ahead-of print articles > Article

Original Article The impact of inflammatory bowel disease on women’s health: a cross sectional study in India: Arshia Bhardwaj^1,*, Arshdeep Singh^1,*, Riya Sharma², Gopal Bhardwaj³, Liza Joshi⁴, Ramit Mahajan¹, Dharmatma Singh¹, Pankaj Kumar⁵, Marla C. Dubinsky⁶, Shaji Sebastian⁷, Vandana Midha⁸, Ajit Sood¹; DOI: https://doi.org/10.5217/ir.2025.00088
Published online: November 14, 2025

¹Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India

²Research and Development Centre, Dayanand Medical College and Hospital, Ludhiana, India

³Department of Internal Medicine, General Hospital, Sector 6, Panchkula, India

⁴Department of Pathology, General Hospital, Sector 6, Panchkula, India

⁵Department of Psychiatry, Dayanand Medical College and Hospital, Ludhiana, India

⁶Division of Pediatric Gastroenterology and Nutrition, Icahn School of Medicine at Mount Sinai, New York, USA

⁷IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals, Hull, UK

⁸Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India

Correspondence to Ajit Sood, Department of Gastroenterology, Dayanand Medical College, Ludhiana, Punjab 141001, India. E-mail: dr_ajit_sood@ dmch.edu

*These authors contributed equally to this study as first authors.

• Received: May 26, 2025 • Revised: July 21, 2025 • Accepted: August 12, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

777 Views
104 Download
1 Web of Science
1 Crossref

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

Abstract

Background/Aims
The gender-specific impact of inflammatory bowel disease (IBD) on women in low- and middle-income countries remains underexplored. We aimed to assess the effects of IBD on different domains of women’s health.
Methods
A cross-sectional study was conducted in women with IBD at a tertiary care center in North India. Women with IBD were interviewed using a structured questionnaire assessing menstrual, reproductive, sexual, mental, social, and financial health, and healthcare access.
Results
Two hundred and two women (median age, 41 years; ulcerative colitis [n = 155, 76.7%]) were enrolled. Anemia was present in 161 women (79.7%), with a median hemoglobin of 10.5 g/dL. Among menstruating women (n = 138), 69 (50%) had irregular cycles, and 39 (28.3%) experienced IBD exacerbations during menstruation. Sexual dysfunction was reported in 82.5% (n = 137/166). Pregnancy-related concerns were common (n = 120, 59.4%), mainly due to risk of heritability and safety of IBD medication. Ten women (4.9%) attributed pregnancy loss to disease activity. Cervical cancer screening (3.0%) and human papillomavirus vaccination (4.0%) rates were low. The median SICC-IBD (social impact of chronic conditions in IBD) score was 0.6. Forty-three women (21.3%) reported difficulties in finding a partner due to IBD. Limited access to IBD specialists (n = 150, 74.3%) and medications (n = 164, 81.2%) were reported in hometown. Fifty-five women (27.2%) relied on loans to manage treatment expenses.
Conclusions
IBD affects women across physical, reproductive, social, and financial domains. Culturally sensitive, multidisciplinary care models are essential to address these unmet needs.
Keywords: Developing countries; Female; Healthcare disparities; Inflammatory bowel diseases; Reproductive health

INTRODUCTION

Inflammatory bowel disease (IBD) is characterized by a complex interplay of genetic, immune, and environmental factors that contribute to its onset, progression, and response to treatment. Epidemiological studies have highlighted sex-based variations in the incidence and prevalence of IBD, clinical manifestations and disease severity [1-3]. The underlying reasons for these gender differences remain incompletely understood but are likely influenced by a combination of genetic, hormonal and psychosocial factors [4-6]. Hormonal fluctuations across various life stages, including puberty, pregnancy, and menopause, influence disease activity and symptom severity [6,7]. Psychosocial challenges, such as mental health concerns, social stigma, and body image issues, add another dimension to the disease burden [8-10]. Additionally, disparities in healthcare access and cultural perceptions of health-seeking behaviors, particularly in low- and middle-income countries (LMICs) where women may encounter barriers to specialized care, contribute to these variations [11,12]. The impact of IBD on women’s health is, therefore, multifaceted, necessitating a comprehensive approach to care.

A nuanced understanding of these gender-specific challenges is crucial to addressing the diverse needs of women to ensure tailored, evidence-based interventions. The present study aims to systematically explore the challenges faced by women living with IBD in LMICs. Guided by the World Health Organization’s holistic definition of health, the present study evaluates the impact of IBD across key domains, including physical, mental, social, environmental, and financial well-being. Additionally, it seeks to identify barriers to care and unmet needs, with the fundamental goal of informing context-specific strategies to enhance the overall health and quality of life of women with IBD.

METHODS

1. Study Design

A cross-sectional, questionnaire-based study with semiquantitative assessments was conducted at a tertiary care institution in northern India from June 2023 to December 2024. Consecutive adult females with an established diagnosis of ulcerative colitis (UC) or Crohn’s disease (CD) were enrolled [13]. Females younger than 18 years of age and those who did not provide informed consent were excluded. The study was approved by the Institutional Ethics Committee of Dayanand Medical College and Hospital (No. DMCH/P/2023/549). Informed consent was obtained from all participants.

2. Data Collection

The lived experiences, challenges, and perspectives of females with IBD, in relation to different domains of health, were captured through a structured questionnaire administered during semi-structured face-to-face interviews. A single investigator (A.B.), trained in the specific interview methodology, conducted all interviews to ensure consistency in data collection and minimize potential interviewer bias.

3. Data Collection Tool

Data were systematically collected using a proforma designed to capture the multidimensional impact of IBD on health, social relationships, financial stability, and environmental factors. The questionnaire included the following sections.

1) Demographics

Basic demographic details were collected. The socioeconomic status was assessed using the Kuppuswamy Socioeconomic Scale, updated for 2023, which categorizes individuals into distinct socioeconomic status classes based on education, occupation, and monthly family income (Supplementary Table 1) [14].

2) Disease Characteristics

Disease characteristics, including type of IBD (UC or CD), disease duration, Montreal classification, disease activity (partial Mayo Score for UC and Harvey Bradshaw Index for CD), extraintestinal manifestations, concomitant therapies, and history of IBD-related surgery, were recorded.

3) Anemia

Hemoglobin levels were measured at recruitment. Anemia was defined as a hemoglobin concentration 11.0 g/dL in pregnant women, and 12.0 g/dL in non-pregnant women [15].

4) Reproductive Health

Data on menstruation, fertility, pregnancy, childbirth, menopause, sexual health, contraceptive access, and reproductive health choices were collected. IBD-related symptoms were assessed in relation to menstruation using a 0–10 visual analog scale (VAS) for severity. Participants provided information on pregnancies, live births, stillbirths, and medical terminations. The survey also addressed difficulties in conception, fertility concerns (rated on a 0–10 VAS), use of assisted reproduction (assisted reproductive technology [ART]/in vitro fertilization [IVF]), contraceptive practices, cervical cancer screening, human papillomavirus (HPV) vaccination, and breastfeeding-related concerns. The Arizona Sexual Experiences Scale (ASEX), a 5-item rating scale assessing sex drive, arousal, vaginal lubrication/penile erection, ability to achieve orgasm, and orgasm satisfaction, was used to assess sexual dysfunction [16].

5) Mental Health

Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS). A score >10 was considered indicative of significant anxiety or depressive symptoms [17]. The Perceived Stress Scale (PSS) was employed to assess the degree to which participants perceived life as unpredictable, uncontrollable, and overwhelming over the past month. Perceived stress levels were categorized as follows: 0–13 (low), 14–26 (moderate), and 27–40 (severe) [18].

6) Body Image

Body image was assessed using the standardized Contour Drawing Rating Scale (CDRS) at diagnosis and at the time of survey. The CDRS includes detailed contour illustrations with graduated body sizes, allowing clear comparison of body proportions. Participants also rated their body image satisfaction on a scale of 0 (not satisfied) to 10 (extremely satisfied).

7) Social Health

The social impact of chronic conditions in IBD (SICC-IBD) scale was employed to evaluate the social dimension of health [19]. The SICC-IBD scale evaluates the broader social impact of IBD, including disruptions in family and social relationships, workplace challenges, and changes in educational or career paths. It comprises 8 item pairs, with the first assessing applicability and the second measuring impact on a 0–5 Likert scale (0 not applicable; 5 extreme impact). The final SICC score is a weighted sum of applicable items, with values approaching 1 indicating greater social burden. Participants were queried about concerns related to acceptance or rejection by potential marriage partners or family members. Additional items assessed the impact of diagnosis on attitudes toward marriage and its influence on family planning discussions during courtship or marriage. Feelings of social alienation, perceived lack of support, and deterioration in personal relationships due to the disease were also evaluated.

8) Environmental Health

The questionnaire included items on access to clean toilet facilities at home and in the workplace, as well as travel-related challenges in both private and public transportation. Dietary difficulties were assessed, along with barriers to accessing IBD specialists, availability of specialists in the local area, distance to the nearest IBD care facility, and challenges in obtaining IBD medications.

9) Financial Health

Financial health was assessed by collecting data on average monthly income, costs of IBD-related treatments, and out-of-pocket expenses. Participants were also asked whether they had to take loans, borrow money, or use personal savings to cover IBD-related medical expenses.

4. Outcomes

The outcomes included the characterization and assessment of the burden and impact of IBD across various domains of health.

5. Statistical Analysis

Categorical variables were presented as frequencies and percentages, while continuous variables were summarized using means and standard deviations or medians and interquartile ranges (IQRs), depending on data distribution. The Kolmogorov-Smirnov test was applied to assess the normality of the data distribution. All analyses were conducted using SPSS version 26.0 (IBM Corp., Armonk, NY, USA).

RESULTS

1. Demographics and Disease Characteristics

During the study period, 230 women with IBD were approached, of whom 202 (87.8%) consented to participate (median age, 41 years; IQR, 32.0–48.2 years) and were interviewed. The majority of participants had UC (n=155, 76.7%), with a median duration of IBD of 5 years (IQR, 3–12 years). The baseline characteristics are summarized in Table 1.

2. Anemia

Anemia was present in 162 women (80.2%), with a median hemoglobin level of 10.5 g/dL (IQR, 9.3–11.7 g/dL). Median transferrin saturation and ferritin levels were 13% (IQR, 7%–23%) and 24 ng/mL (IQR, 11–49 ng/mL), respectively. Among those with anemia, iron deficiency anemia was present in 115 women (71.4%). Macrocytic anemia secondary to vitamin B₁₂ deficiency was observed in 7 women (4.3%), while 40 (24.8%) had normocytic normochromic anemia.

3. Physical Health

Among the study participants, 138 women (68.3%) were menstruating. The median age at menarche was 12 years (IQR, 12–14 years). Menstrual cycles were predominantly irregular in 58 women (42.0%) and consistently irregular in 11 (7.9%). Most women (n=72, 52.2%) reported moderate menstrual flow, while 29 (21.0%) reported heavy flow and 10 (7.2%) variable patterns. Fatigue emerged as the most severe symptom on VAS (Fig. 1A).

IBD symptom exacerbation during menstruation was reported by 39 women (28.2%), including 4 (2.9%) who experienced worsening with each cycle; the remaining 99 (71.7%) reported no change. A total of 64 women (31.7%) were postmenopausal or had undergone hysterectomy, with a median age at menopause of 44 years (IQR, 42–45 years).

Of the 202 women surveyed, 165 (81.7%) were sexually active. Among them, 39 (23.6%) reported occasional and 5 (3.0%) frequent difficulties during sexual activity due to IBD-related symptoms. Pelvic pain was the most commonly reported symptom (n=122, 73.5%), followed by abdominal pain (n=93, 56.0%). Pain-related interruption of intercourse was reported frequently by 55 (33.1%) women and occasionally by 59 (35.5%) (Fig. 1B).

Among the 165 participants assessed using the ASEX, 137 participants (83.0%) met the criteria for sexual dysfunction, while 28 (17.0%) participants did not report any dysfunction. Further analysis of ASEX scoring patterns showed that a total score ≥19 was observed in 45 participants (27.1%). Additionally, 82 participants (49.4%) reported a score >5 on at least one item, and 137 (83.0%) participants met the criterion of a score >4 on any three items. Regarding reproductive health counseling, 178 (88.1%) women had never received advice on contraception, only 5 (2.5%) had received guidance on cervical cancer screening, and 8 (4.0%) had received the HPV vaccine.

One hundred and sixty-five women (81.68%) reported a history of pregnancy, with a median age at first pregnancy of 23 years (IQR, 22–25 years). Among these, 35 (21.2%) experienced spontaneous abortion, 19 (11.5%) underwent medical termination for unwanted pregnancy, and 5 (3.0%) reported stillbirth (Fig. 1C). Assisted reproduction (IVF/ART) was used by 2 (0.99%) women, and pregnancy loss was directly attributed to IBD activity in 10 (4.95%) women.

Concerns regarding conception were reported by 120 (59.4%) women. The most common concern was fear of heritability of IBD (n=112, 55.4%), followed by concerns about congenital abnormalities (n=87, 43.1%), pregnancy complications (n=77, 38.1%), adverse effects of medication (n=77, 38.1%), financial constraints (n=28, 13.9%), and lack of support or difficulty in child-rearing (n=18, 8.9%) (Fig. 1D). Concerns during breastfeeding included potential adverse effects of medication on the child (n=65, 32.2%) and transmission of IBD through breastfeeding (n=96, 47.5%).

4. Mental Health

Psychological well-being was assessed using validated scales for stress, depression, and anxiety. On the PSS, 192 (95.0%) women reported moderate stress with scores ranging from 14 to 26, while an additional 9 (4.5%) women reported high stress, defined as a score of ≥ 27. Depressive symptoms were evaluated using the HADS. Of the participants, 90 (44.6%) women scored between 11 and 15, and 62 (30.7%) women scored between 16 and 21 on the depression subscale - both score ranges indicative of clinically relevant depressive symptoms. Similarly, the anxiety subscale of the HADS revealed that 77 (38.1%) women scored between 11 and 15, and 65 (32.2%) women scored between 16 and 21, indicating moderate to severe symptoms of anxiety in over 70% of participants (70.3%).

5. Body Image

Body image was assessed using the CDRS, a visual tool that captures perceived body shape by having participants select from standardized body silhouettes ranging from lean to obese. At the time of diagnosis, the most frequently selected body image was silhouette “C” (n=60, 29.7%), which typically represents a normal or mildly lean body type. At the time of assessment, the most commonly selected silhouette shifted to “D” (n=63, 31.2%), indicating a perceived increase in body size or a change in self-perception over the disease course or during treatment. In addition to silhouette selection, participants rated their satisfaction with their current body image using a 0–10 VAS, where 0 indicated complete dissatisfaction and 10 indicated complete satisfaction. The median satisfaction score was 5.00 (IQR 4.00–6.00), reflecting ambivalence regarding body image.

6. Social Health

Among 202 women surveyed, 43 (21.3%) reported difficulty in finding a partner, and 42 (20.8%) experienced direct rejections due to their IBD diagnosis. Additionally, 54 (26.7%) felt that IBD negatively influenced their perspective on marriage. Of the respondents, 84 (41.6%) felt unaccepted within their families, while 134 of 175 (76.6%) married women reported lack of acceptance from their in-laws. Feelings of non-acceptance were also reported in the workplace by 21 of 35 (60.0%) women, and in the broader social circle by 117 of 202 (57.9%) women (Fig. 2A). The SICC-IBD score was used to assess the psychosocial burden of IBD across personal, interpersonal, and occupational domains. The median SICC-IBD score was 0.6 (IQR, 0.4–0.6), indicating a moderate to high level of perceived social impact among the participants. The majority of women (n=90, 44.5%) scored within the 0.41–0.60 range, while 60 (29.7%) women scored between 0.21–0.40 (Fig. 2B). Relationship breakups were reported by 94 women (46.5%), and interpersonal difficulties with partners, family members, friends, or colleagues were reported by 106 women (52.5%). Functional limitations were also highly prevalent. Nearly all respondents (n=198, 98.0%) reported some degree of difficulty performing physical activities of daily living. The occupational consequences of IBD were significant. Forty-three (21.3%) women reported loss of employment, while 51 (25.2%) felt that their earning potential was negatively affected. Thirty-five (17.3%) participants had to change jobs due to the disease, and a similar number expressed ongoing concerns about job security. Educational pursuits were also affected, with 43 (21.3%) women reporting that their academic progression was adversely impacted by IBD (Fig. 2C).

7. Environmental Health

At home, 195 women (96.5%) reported access to clean toilet facilities. However, only 23 of 35 (65.7%) employed women had uninterrupted access to clean toilets at the workplace. Access during travel was more limited, with 144 (71.3%) women reporting difficulty in finding clean facilities. Following an IBD diagnosis, 145 (71.8%) women experienced difficulty in making dietary changes. Common challenges included the need to cook separately from family meals (n=145, 71.8%), excessive dietary restrictions (n=128, 63.4%), conflicting advice from friends/family (n=58, 28.7%) and increased cost of meals (n=58, 28.7%) (Fig. 3A). A total of 150 (74.3%) women lacked access to an IBD specialist in their hometown and had to travel to another city for consultation. An additional 20 women (9.9%) had local access but chose to consult elsewhere to maintain privacy. Prolonged travel was common, with 161 (79.7%) women reporting travel times exceeding 4 hours (Fig. 3B). Access to medications was also a challenge, with 164 (81.2%) women experiencing varying degrees of difficulty in procuring IBD drugs locally (Fig. 3C).

8. Financial Health

Of the cohort, 35 (17.3%) women were employed. Among them, the median monthly income was Indian Rupee (INR) 27,500 (USD 316; IQR, INR 19,500 [USD 224]–INR 52,500 [USD 603]), while the median income for the entire cohort was INR 7,400 (USD 85). The median monthly expenditure on medications was INR 7,500 [USD 86.00; IQR, INR 6,500 [USD 74]–INR 9,000 [USD 103]). Most women (n=187, 92.6%) reported that the cost of therapy was covered by their spouse or family. Financial difficulties in affording IBD medications were reported by 73 (36.1%) women, and 55 (27.2%) frequently relied on loans to manage expenses.

9. Effect of Disease Type and Disease Activity

A subgroup analysis was conducted to compare the differential impact in women with UC and CD. Women with UC were younger, both in age at enrolment and at the time of diagnosis, and exhibited significantly higher median scores on the PSS. When stratified by disease activity, active UC was associated with higher mean PSS scores and elevated anxiety levels, with a greater proportion of patients reporting HADS anxiety scores >10. Among patients with CD, active disease was significantly associated with higher rates of anemia, symptom exacerbation during menstruation, lower pregnancy rates, and increased median scores for both anxiety and depression on the HADS (Table 2).

DISCUSSION

We evaluated the impact of IBD across different domains of health on women in a LMIC (Fig. 4). The median age of the study cohort was 41 years, consistent with the global trends of IBD peaking in early-to-middle adulthood [20]. This age group commonly faces challenges in managing disease alongside professional, caregiving, and personal health responsibilities. The cohort’s median of 3 siblings and birth order of 2 reflects familial structures typical of LMICs where extended families often provide emotional and logistical support in management of chronic diseases [21,22].

About one-third of women in this cohort reported worsening of IBD symptoms during menstruation, consistent with previous reports of exacerbated gastrointestinal and systemic symptoms during menses [23,24]. These symptom flares have significant clinical and societal implications, including increased absenteeism, reduced productivity, and heightened physical and psychological distress, highlighting the need for workplace accommodations such as flexible or remote work during menstruation.

The relationship between IBD and menopausal age is understudied in India and other LMICs. The median age of menopause in our cohort was 44 years, which is lower than the average reported in both national and international data. Indian studies have documented a mean age at menopause of approximately 46.2 to 46.6 years, significantly earlier than that of women in many Western countries, where the average age is around 50 to 51 years [25-27]. Sociocultural, family planning, and socioeconomic factors likely contribute to this difference [28,29]. Earlier menopause prolongs the postmenopausal period, increasing the risk of cardiovascular disease, osteoporosis, and hormone-related cancers in affected women.

Sexual dysfunction is prevalent among women with IBD, with reported rates ranging from 50% to 90%, significantly exceeding those observed in the general population [30-32]. Integrating sexual health discussions into routine clinical care is vital and can be made feasible through context-appropriate strategies. Brief, validated screening tools such as the ASEX can be incorporated into routine assessments, and healthcare providers can be trained in empathetic, culturally sensitive communication. Opportunistic screening during chronic disease consultations, task-shifting to trained nurses or counsellors, and ensuring privacy in clinical settings can facilitate this disclosure [33]. Educational materials and mHealth tools may further support awareness and engagement.

Significant concerns were noted regarding heritability, congenital abnormalities, pregnancy complications, and the impact of medications on fetal development. Genetic predisposition to IBD also contributes to anxiety about transmission to offspring. Prior studies have identified lack of desire for parenthood and perceived support for child-rearing as key factors influencing voluntary childlessness, which are critical considerations in preconception counselling [34].

In our cohort, only 2.47% women reported having ever received guidance on cervical cancer screening, and 3.96% had received the HPV vaccine, indicating significant gaps in preventive health practices. These figures are consistent with low broader national trends in India, where overall HPV vaccination coverage among eligible women has been estimated at < 2% [35]. Cervical cancer screening rates are similarly low across the country. Two studies report a national average prevalence of screening for cervical cancer to be 1.9% with marked interstate variation, from as low as 0.2% in West Bengal and Assam to 10.1% in Tamil Nadu [36,37]. The extremely low uptake of both HPV vaccination and cervical cancer screening observed in our study reinforces the urgent need for targeted educational and preventive strategies, particularly among women with chronic diseases like IBD, who may face additional barriers to accessing routine gynecologic care. Pregnancy complications in this study included spontaneous abortions, stillbirths, and terminations due to active IBD. The stillbirth rate in India, based on the National Family Health Survey, is 9.7 per 1000 births, while the UK reports a rate of 0.4% [38,39]. In the current IBD cohort, stillbirth incidence was twice that of the general Indian population and five times higher than rates in developed countries. This elevated risk in women with IBD exacerbates the existing stillbirth burden in LMICs, posing significant public health challenges by increasing demands for specialized maternal-fetal care, enhanced prenatal monitoring, and optimized disease management.

Significant social and emotional challenges related to marriage and family planning were reported, highlighting stigma and misconceptions associated with IBD. Perceived rejection was most prominent from in-laws, followed by workplace and social environments. Elevated SICC-IBD scores, along with high rates of relationship difficulties, job loss, and disruptions to daily life and education, further call attention to the impact of IBD on women’s social and professional functioning.

The women in current cohort also faced unique and amplified challenges related to toilet accessibility. Implementing the IBD passport, a disease card with priority access to toilets, in LMICs is especially crucial for women, to ensure dignity, security, and equitable access to facilities, ultimately improving their participation in professional and social life [40].

Access to specialized IBD care remains a significant challenge, with only 26% of women having an IBD specialist locally. Many women were required to travel long distances for care, which, combined with societal and caregiving responsibilities, hinders regular follow-up. These barriers negatively affect reproductive health, pregnancy outcomes, and overall well-being. High costs of treatment underline the need for improved insurance coverage, subsidized care, and policy interventions including financial counselling and patient assistance programs to reduce the economic burden of IBD management, especially in areas where majority of the women are unemployed.

The strengths of the study include a large, age-diverse sample and a comprehensive, focused questionnaire covering multiple health domains. Data collection consistency was ensured by using a single interviewer. Importantly, this is the first study from a LMIC to examine the unique challenges faced by women with IBD, distinct from those in developed settings. The limitations include its single-center design, lack of endoscopic disease activity scores at baseline, use of some non-validated, region-specific sections in the questionnaire, and a cross-sectional cohort without longitudinal follow-up or a control group, restricting generalizability and direct comparison to women without IBD. Nonetheless, the study provides valuable insights into the health impact on women with IBD, aiming to inform evidence-based policies and tailored healthcare interventions.

In conclusion, this study highlights the complex impact of IBD on women in LMICs, emphasizing the need for gender-sensitive, comprehensive care. An integrated model combining effective IBD management with reproductive health services and psychosocial support is essential. Achieving healthcare equity for women with IBD must be recognized as a fundamental right, necessitating sustained clinical and policy-level action.

NOTES

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

Dubinsky MC has received consultancy fees from AbbVie, Arena, BMS, Eli Lilly, Janssen, Pfizer, Prometheus Biosciences and Takeda. Sebastian S has received consulting fees from Celltrion, BMS Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene, Lilly, and Tillots Pharma; has received payment or honoraria for lectures from AbbVie, Takeda, Celltrion, Pfizer, Biogen, AbbVie, Janssen, Merck, Warner Chilcott, Falk Pharma, Janssen, and Lilly. Sood A received honorarium for speaker events from Pfizer India and Takeda India. Sood A is also a member of the Editorial Board but was not involved in the peer review process or in any decision regarding this manuscript. The remaining authors disclose no conflicts.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author Contributions

Conceptualization: Bhardwaj A, Singh A, Sood A. Data curation: Bhardwaj A, Singh D. Data interpretation: Bhardwaj A, Singh A, Sood A. Formal analysis: Bhardwaj A, Singh A, Sharma R, Sood A. Methodology: Bhardwaj A, Singh A, Kumar P, Midha V, Sood A. Project administration: Bhardwaj A, Singh A, Sood A. Resources: Bhardwaj A, Singh A, Sharma R, Bhardwaj G, Joshi L, Sood A. Supervision: Kumar P, Midha V, Sood A. Validation: Bhardwaj A, Singh A, Bhardwaj G, Joshi L, Sood A. Visualization: Bhardwaj A, Singh A, Sharma R, Bhardwaj G, Joshi L, Mahajan R, Dubinsky MC, Sebastian S, Midha V, Sood A. Writing – original draft: Bhardwaj A, Singh A, Sood A. Writing – review & editing: all authors. Approval of final manuscript: all authors.

Additional Contributions

The authors acknowledge the contribution from Ms. Riaz Bhardwaj (Freelance Economic Consultant, Private Sector) in creating the illustrations and graphics for the manuscript.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Table 1.

Kuppuswamy Scale (Updated for 2023)

ir-2025-00088-Supplementary-Table-1.pdf

Fig. 1.

Impact of IBD on menstrual and sexual health and pregnancy. (A) severity of symptoms during menstruation (median value on VAS), (B) disruption of sexual act due to abdominal/pelvic pain, (C) complications during pregnancy, (D) reasons for apprehension about conception. VAS, visual analog scale; IBD, inflammatory bowel disease.

Fig. 2.

mpact of IBD on social domain of health (A) self-perceived perception of acceptance in society, (B) the distribution of social impact of chronic conditions in IBD (SICC-IBD) scores, and (C) number of patients responding in affirmation to different questions in the SICC-IBD score. IBD, inflammatory bowel disease.

Fig. 3.

The environmental impacts of IBD (A) major challenges faced while making changes to the diet, post-IBD diagnosis, (B) access to IBD medicines in hometown, (C) travel time from home to IBD care facility. IBD, inflammatory bowel disease.

Fig. 4.

The multifaceted impact of IBD on women’s health. ASEX, Arizona Sexual Experiences Scale; HPV, human papillomavirus; IBD, inflammatory bowel disease; INR, Indian Rupee; SICC-IBD, social impact of chronic conditions in IBD.

Table 1.

Baseline Characteristics (n=202)

Demographics	Value
Age (yr)	41.00 (32.00–48.25)
Body mass index (kg/m²)	23.06 (20.07–25.74)
Marital status
Married	167 (82.67)
Unmarried	27 (13.36)
Widow/divorcee	8 (3.96)
Kuppuswamy socioeconomic class
Upper lower	18 (8.91)
Lower middle	99 (49.00)
Upper middle	67 (33.16)
Upper	18 (8.91)
Disease characteristics
Ulcerative colitis	155 (76.73)
Disease extent
Proctitis	45 (29.03)
Left sided colitis	88 (56.77)
Pancolitis	22 (14.19)
Disease activity at enrolment (partial Mayo score)^a
Remission	59 (38.06)
Mild	66 (42.58)
Moderate	22 (14.19)
Severe	8 (5.16)
Crohn’s disease	47(23.26)
Disease classification
Age at diagnosis (yr)
< 17	2 (4.25)
17–40	25 (53.19)
> 40	20 (42.55)
Disease location
Ileal	14 (29.78)
Colonic	14 (29.78)
Ileocolonic	19 (40.42)
Disease behavior
Non stricturing, non-penetrating	33 (70.21)
Stricturing	10 (21.27)
Fistulizing	4 (8.51)
Perianal disease	4 (8.51)
Disease activity at enrolment (HBI)^b
Remission	31 (65.95)
Mild	11 (23.40)
Moderate	5 (10.63)
Extraintestinal manifestations
Peripheral arthritis	42 (20.79)
Axial arthritis	21 (10.39)
Peripheral + axial arthritis	8 (3.96)
Pyoderma gangrenosum	2 (0.99)
Erythema nodosum	2 (0.99)
Primary sclerosing cholangitis	1 (0.49)
Nephrolithiasis	4 (1.98)
Episcleritis	2 (0.99)
Concomitant medications
Oral 5-aminosalicylates	194 (96.04)
Rectal 5-aminosalicylates	98 (48.51)
Corticosteroids
Prednisolone	23 (11.38)
Budesonide	51 (25.24)
Thiopurines	36 (17.82)
Tofacitinib	80 (39.60)
Anti-TNFs	8 (3.96)
Vedolizumab	4 (1.98)
Ustekinumab	3 (1.48)
IBD-related surgery
Small bowel resection	5 (2.47)
Proctocolectomy with IPAA	3 (1.48)
Perianal fistula surgery	3 (1.48)
Comorbid illness
Diabetes mellitus	5 (2.47)
Hypertension	7 (3.46)
Hypothyroidism	15 (7.42)
Celiac disease	3 (1.48)
Family dynamics and family history
Number of siblings	3 (2–4)
Birth order	2 (1–3)
Family history of IBD	8 (3.96)

Values are presented as median (interquartile range) or number (%).

^a Partial Mayo Score (PMS): clinical remission (PMS 0-1), mild (PMS 2-4), moderate (PMS 5-7), severe (PMS >7).

^b HBI: clinical remission (HBI <5), mild (HBI 5–7), moderate (HBI 8–15), severe (HBI >15).

TNF, tumor necrosis factor; IBD, inflammatory bowel disease; IPAA, ileal pouch anal anastomosis; HBI, Harvey Bradshaw Index.

Table 2.

Impact of Disease Type and Disease Activity on Key Domains of Health

	UC (n = 155)	CD (n = 47)	P-value	UC active disease (n = 96)	UC in remission (n = 59)	P-value	CD active disease (n = 16)	CD in remission (n = 31)	P-value
Patient and disease characteristics
Age (yr)	39.6 ± 10.8	44.2 ± 13.3	0.020	38.9 ± 10.5	40.9 ± 11.2	0.260	40.6 ± 13.1	46.0 ± 13.2	0.200
Age at diagnosis (yr)	31.1 ± 10.3	37.1 ± 13.4	0.001	30.6 ± 10.1	32.1 ± 10.7	0.390	33.5 ± 12.5	39.0 ± 13.6	0.180
Body mass index (kg/m²)	23.5 ± 4.5	22.3 ± 4.5	0.110	23.2 ± 4.6	23.8 ± 4.2	0.420	20.3 ± 3.3	23.3 ± 4.8	0.040
Total Kuppuswamy score	15.0 (13.0–17.0)	16.0 (13.0–18.0)	0.120	15.0 (13.0–18.0)	15.0 (12.0–16.0)	0.600	15.5 (13.2–17.0)	16.0 (13.0–19.0)	0.680
Disease duration (yr)	5.0 (2.0–12.0)	6.0 (3.0–12.0)	0.350	5.0 (3.0–11.7)	6.0 (3.0–13.0)	0.310	5.5 (1.2–13.0)	4.0 (3.0–11.0)	0.910
Partial Mayo score	2.0 (0.0–4.0)	-	-	3.0 (3.0–5.0)	0.0 (0.0–0.0)	< 0.001	-	-	-
Harvey Bradshaw Index	-	3.0 (2.0–5.0)	-	-	-	-	5.0 (5.0–8.7)	2.0 (1.0–3.0)	< 0.001
Concomitant therapy
5-Aminosalicylates	153 (98.7)	41 (87.2)	< 0.001	95 (98.9)	58 (98.3)	0.720	15 (93.8)	26 (83.9)	0.340
Corticosteroids	56 (36.1)	18 (38.3)	0.780	46 (47.9)	10 (16.9)	< 0.001	8 (50.0)	10 (32.2)	0.240
Thiopurines	21 (13.5)	15 (31.9)	0.004	13 (13.5)	8 (13.5)	0.990	4 (25.0)	11 (35.5)	0.470
Biologics/small molecules	69 (44.5)	26 (55.3)	0.190	43 (44.8)	26 (44.1)	0.930	8 (50.0)	18 (58.1)	0.600
Extraintestinal manifestations
Peripheral arthritis	29 (18.7)	13 (27.7)	0.180	17 (17.7)	12 (20.3)	0.680	5 (31.3)	8 (25.8)	0.690
Axial arthritis	15 (9.7)	6 (12.8)	0.540	13 (13.5)	2 (3.4)	0.040	1 (6.3)	5 (16.1)	0.340
Deep venous thrombosis	3 (1.9)	0	0.330	1 (1.0)	2 (1.0)	0.290	0	0	-
Gall stone	7 (4.5)	7 (14.9)	0.010	4 (4.2)	3 (5.1)	0.800	1 (6.3)	6 (19.4)	0.230
Pyoderma gangrenosum	2 (1.3)	0	0.430	1 (1.0)	1 (1.7)	0.700	0	0 (0.0)	-
Erythema nodosum	1 (0.6)	1 (2.1)	0.360	0	1 (1.7)	0.200	0	1 (3.2)	0.470
Scleritis/episcleritis	0	2 (4.3)	0.010	0	0	-	2 (12.5)	0	0.050
Nephrolithiasis	4 (2.6)	0	0.260	3 (3.1)	1 (1.7)	0.600	0	0	-
Primary sclerosing cholangitis	1 (0.6)	0	0.580	0	1 (1.7)	0.200	0	0	-
Family history of IBD	5 (3.2)	3 (6.4)	0.330	1 (1.0)	4 (6.8)	0.050	1 (6.3)	2 (6.5)	0.970
Evaluation for anemia
Hemoglobin (g/dL)	10.4 ± 1.7	10.2 ± 1.9	0.350	10.5 ± 1.7	10.2 ± 1.8	0.290	9.2 ± 1.6	10.6 ± 1.9	0.020
Anemia present	123 (79.3)	39 (83.0)	0.580	76 (79.2)	47 (79.7)	0.940	16 (100.0)	23 (74.2)	0.030
Iron deficiency anemia	91 (58.7)	24 (51.1)	0.350	56 (58.3)	35 (59.3)	0.900	12 (75.0)	12 (38.7)	0.020
Reproductive health
Age at menarche (yr)	13.1 ± 1.8	13.1 ± 1.6	0.930	13.1 ± 1.8	13.1 ± 1.8	0.860	12.9 ± 1.7	13.2 ± 1.6	0.610
Age at menopause/hysterectomy (yr)^a	43.1 ± 4.1	42.2 ± 5.2	0.460	42.7 ± 4.6	43.7 ± 3.3	0.440	41.2 ± 5.5	42.4 ± 5.2	0.690
Are your periods regular?
Always irregular	8 (5.2)	3 (6.4)	0.750	3 (3.1)	5 (8.5)	0.140	1 (6.3)	2 (6.5)	0.970
Mostly irregular	47 (30.3)	11 (23.4)	0.360	34 (35.4)	13 (22.0)	0.080	5 (31.3)	6 (19.4)	0.360
Mostly regular	56 (36.1)	13 (27.7)	0.290	32 (33.3)	24 (40.7)	0.350	6 (37.5)	7 (22.6)	0.280
Not applicable, post menopausal	44 (28.4)	20 (42.6)	0.070	27 (28.1)	17 (28.8)	0.920	4 (25.0)	16 (51.6)	0.080
Periods worsen IBD activity	34 (21.9)	5 (10.6)	0.090	22 (22.9)	12 (20.3)	0.700	4 (25.0)	1 (3.2)	0.020
Marital status
Married	132 (85.2)	35 (74.5)	0.090	83 (86.5)	49 (83.1)	0.560	10 (62.5)	25 (80.6)	0.180
Unmarried	18 (11.6)	9 (19.1)	0.190	10 (10.4)	8 (13.6)	0.550	5 (31.3)	4 (12.9)	0.130
Widow	3 (1.9)	1 (2.1)	0.930	2 (2.1)	1 (1.7)	0.860	0 (0.0)	1 (3.2)	0.470
Divorced	2 (1.3)	2 (4.3)	0.190	1 (1.0)	1 (1.7)	0.700	1 (6.3)	1 (3.2)	0.620
Age at marriage (yr)	22.6 ± 2.8	21.7 ± 2.6	0.800	22.6 ± 2.7	22.8 ± 2.7	0.760	21.1 ± 2.2	22.0 ± 2.8	0.320
Diagnosis of IBD before marriage	25 (16.1)	3 (6.4)	0.090	17 (17.7)	8 (13.6)	0.500	1 (6.3)	2 (6.5)	0.970
Unmarried, facing difficulty in marriage^b	18 (100.0)	9 (100.0)	0.180	10 (10.4)	8 (13.6)	0.540	5 (31.3)	4 (12.9)	0.130
Ever been pregnant	128 (82.6)	37 (78.7)	0.530	78 (81.3)	50 (84.7)	0.590	10 (62.5)	27 (87.1)	0.050
Advised about contraception by physician	20 (12.9)	4 (8.5)	0.410	14 (14.5)	6 (10.2)	0.430	1 (6.3)	3 (9.7)	0.690
Still births	3 (1.9)	2 (4.2)	0.360	1 (1.0)	2 (3.4)	0.290	0	2 (6.4)	0.300
Spontaneous abortion	26 (16.8)	9 (19.1)	0.720	15 (15.6)	11 (18.6)	0.630	4 (25.0)	5 (16.1)	0.460
Medical termination for unwanted pregnancy	14 (9.0)	5 (10.6)	0.740	6 (6.3)	8 (13.6)	0.120	0	5 (16.1)	0.090
Pregnancy getting terminated due to IBD activity	9 (5.8)	1 (2.1)	0.300	6 (6.3)	3 (5.1)	0.760	0	1 (3.2)	0.470
Concerns about breastfeeding the child while being on IBD medicines	53 (34.2)	12 (25.5)	0.260	37 (38.5)	16 (27.1)	0.140	2 (12.5)	10 (32.3)	0.140
Apprehensive about transmission of disease while breastfeeding	72 (46.5)	24 (51.1)	0.580	48 (50.0)	24 (40.7)	0.260	8 (50.0)	16 (51.6)	0.910
Received advice about cervical cancer screening	2 (1.3)	3 (6.4)	0.050	2 (2.1)	0	0.260	0	3 (9.7)	0.200
Received HPV vaccine	6 (3.9)	2 (4.3)	0.900	4 (4.2)	2 (3.4)	0.800	0	2 (6.5)	0.300
Social health
Total SICC-IBD score	0.5 ± 0.2	0.6 ± 0.2	0.280	0.5 ± 0.1	0.5 ± 0.2	0.270	0.6 ± 0.2	0.6 ± 0.1	0.940
SICC-IBD score
< 0.5	64 (41.3)	17 (36.2)	0.500	38 (39.6)	26 (44.1)	0.580	6 (37.5)	11 (35.5)	0.890
≥ 0.5	91 (58.7)	30 (63.8)		58 (60.4)	33 (55.9)		10 (62.5)	20 (64.5)
Mental health
Total score on Perceived Stress Scale	21.0 (18.0–23.0)	19.0 (18.0–22.0)	0.020	21.0 (19.0–24.0)	20.0 (18.0–22.0)	0.050	20.0 (19.0–22.0)	18.0 (18.0–22.0)	0.190
Perceived Stress Scale score
14–26	146 (94.2)	46 (97.8)	0.300	89 (92.7)	57 (96.6)	0.310	15 (37.5)	31 (100.0)	0.160
≥ 27	8 (5.2)	1 (2.1)	0.370	6 (6.2)	2 (3.4)	0.430	1 (6.2)	0	0.160
Total anxiety score on HADS	14.0 (9.0–17.0)	14.0 (8.0–17.0)	0.690	14.0 (12.0–18.0)	13.0 (8.0–14.0)	0.010	16.5 (10.2–21.0)	13.0 (8.0–14.0)	0.040
Anxiety score on HADS > 10	113 (72.9)	29 (61.7)	0.140	76 (79.2)	37 (62.7)	0.020	12 (75.0)	17 (54.8)	0.180
Total depression score	14.0 (11.0–16.0)	14.0 (10.0–17.0)	0.900	14.0 (11.0–17.0]	13.0 (10.0–15.0)	0.740	16.5 (14.0–21.0)	14.0 (9.0–15.0)	0.040
Depression score on HADS > 10	117 (75.5)	35 (74.5)	0.880	75 (78.1)	42 (71.2)	0.330	13 (81.2)	22 (70.9)	0.440
Sexual health
Total Score ASEX^c	15.0 (15.0–20.0)	15.0 (15.0–18.0)	0.650	15.0 (15.0–20.0)	15.0 (15.0–20.0)	0.750	18.0 (15.0–25.0)	15.0 (15.0–18.0)	0.370
Sexual dysfunction (ASEX)	107 (69.0)	30 (63.8)	0.500	69 (71.9)	38 (64.4)	0.330	10 (62.5)	20 (64.5)	0.890

Values are presented as mean±standard deviation, median (interquartile range), or number (%).

^a A total of 44 women with UC and 20 women with CD were either postmenopausal or had undergone hysterectomy.

^b The number of unmarried women was 18 in the UC group and 9 in the CD group.

^c Sexual activity was reported by 131 women with UC and 34 women with CD.

UC, ulcerative colitis; CD, Crohn’s disease; IBD, inflammatory bowel disease; HPV, human papilloma virus; SICC-IBD, social impact of chronic conditions in IBD; HADS, hospital anxiety and depression scale; ASEX, Arizona Sexual Experience Scale.

REFERENCES

1. Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western Countries. Gastroenterology 2018;155:1079–1089.Article PubMed
2. Shah SC, Khalili H, Chen CY, et al. Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region. Aliment Pharmacol Ther 2019;49:904–911.Article PubMed PDF
3. Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol 2020;13:1756284820915043.Article PubMed PMC PDF
4. Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut 2013;62:1153–1159.Article PubMed
5. Gomez A, Luckey D, Taneja V. The gut microbiome in autoimmunity: sex matters. Clin Immunol 2015;159:154–162.Article PubMed PMC
6. Rolston VS, Boroujerdi L, Long MD, et al. The influence of hormonal fluctuation on inflammatory bowel disease symptom severity: a cross-sectional cohort study. Inflamm Bowel Dis 2018;24:387–393.Article PubMed PMC
7. De Simone V, Matteoli G. Estrogen-mediated effects underlie gender bias in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 2018;5:638–639.Article PubMed PMC
8. Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:359–370.Article PubMed
9. Singh A, Bhardwaj A, Tripathi A, et al. Burden of anxiety, depression and perceived stress in patients with inflammatory bowel disease: a cohort study from North India. Dig Dis Sci 2024;69:775–790.Article PubMed PDF
10. Simeone S, Mercuri C, Cosco C, Bosco V, Pagliuso C, Doldo P. Enacted stigma in inflammatory bowel disease: an Italian Phenomenological Study. Healthcare (Basel) 2023;11:474.Article PubMed PMC
11. Terefe B, Workneh BS, Zeleke GA, et al. Uncovering women’s healthcare access challenges in low- and middle-income countries using mixed effects modelling approach: insights for achieving the Sustainable Development Goals. PLoS One 2025;20:e0314309.Article PubMed PMC
12. Shatilwe JT, Kuupiel D, Mashamba-Thompson TP. Evidence on access to healthcare information by women of reproductive age in low- and middle-income countries: scoping review. PLoS One 2021;16:e0251633.Article PubMed PMC
13. Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144–164.Article PubMed
14. Radhakrishnan M, Nagaraja SB. Modified Kuppuswamy socioeconomic scale 2023: stratification and updates. Int J Community Med Public Health 2023;10:4415–4418.Article PDF
15. World Health Organization. Anaemia [Internet]. c2025;[cited 2025 Mar 15]. https://www.who.int/data/nutrition/nlis/info/anaemia.
16. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25–40.Article PubMed
17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–370.Article PubMed
18. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983;24:385–396.Article PubMed
19. Smith JJ, Netuveli G, Sleight SP, et al. Development of a social morbidity score in patients with chronic ulcerative colitis as a potential guide to treatment. Colorectal Dis 2012;14:e250–e257.Article PubMed
20. Dharni K, Singh A, Sharma S, et al. Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019). Indian J Gastroenterol 2024;43:188–198.Article PubMed PDF
21. Duminy J, Cleland J, Harpham T, Montgomery MR, Parnell S, Speizer IS. Urban family planning in low- and middle-income countries: a critical scoping review. Front Glob Womens Health 2021;2:749636.Article PubMed PMC
22. Bradshaw CJA, Perry C, Judge MA, Saraswati CM, Heyworth J, Le Souëf PN. Lower infant mortality, higher household size, and more access to contraception reduce fertility in low- and middle-income nations. PLoS One 2023;18:e0280260.Article PubMed PMC
23. Bernstein MT, Graff LA, Targownik LE, et al. Gastrointestinal symptoms before and during menses in women with IBD. Aliment Pharmacol Ther 2012;36:135–144.Article PubMed
24. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol 1998;93:1867–1872.Article PubMed
25. Moktan VP, Daoud ND, Tremaine WJ, et al. A cohort study of the age at menopause in female patients with and without inflammatory bowel disease. Crohns Colitis 360 2022;4:otac027.Article PubMed PMC PDF
26. Ahuja M. Age of menopause and determinants of menopause age: a PAN India survey by IMS. J Midlife Health 2016;7:126–131.Article PubMed PMC
27. Prasad JB, Tyagi NK, Verma P. Age at menopause in India: a systematic review. Diabetes Metab Syndr 2021;15:373–377.Article PubMed
28. Pallikadavath S, Ogollah R, Singh A, Dean T, Dewey A, Stones W. Natural menopause among women below 50 years in India: a population-based study. Indian J Med Res 2016;144:366–377.PubMed PMC
29. Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am 2011;38:425–440.Article PubMed PMC
30. Nardone OM, Calabrese G, Bertin L, et al. Prevalence of sexual dysfunction in inflammatory bowel disease: systematic review and meta-analysis. J Crohns Colitis 2025;19:jjae133.Article PubMed PDF
31. Boyd T, de Silva PS, Friedman S. Sexual dysfunction in female patients with inflammatory bowel disease: an overview. Clin Exp Gastroenterol 2022;15:213–224.Article PubMed PMC PDF
32. Singh N, Sharma P, Mishra N. Female sexual dysfunction: Indian perspective and role of Indian gynecologists. Indian J Community Med 2020;45:333–337.Article PubMed PMC
33. Singh A, Bhardwaj A, Sharma R, Midha V, Sood A. Developing IBD counsellors in low- and middle-income countries: bridging gaps in patient care. EClinicalMedicine 2025;83:103218.Article PubMed PMC
34. Selinger CP, Steed H, Purewal S, Homer R, NIHR BioResource; Brookes M. Factors associated with family planning status and voluntary childlessness in women of childbearing age with inflammatory bowel diseases. J Clin Med 2023;12:4267.Article PubMed PMC
35. Sankaranarayanan R, Basu P, Kaur P, et al. Current status of human papillomavirus vaccination in India’s cervical cancer prevention efforts. Lancet Oncol 2019;20:e637–e644.Article PubMed
36. Muthuramalingam MR, Muraleedharan VR. Patterns in the prevalence and wealth-based inequality of cervical cancer screening in India. BMC Womens Health 2023;23:337.Article PubMed PMC PDF
37. Subramanian SS, Bhaskarapillai B, Jayakrishnan R. Female cancer screening in India: results from the National Family Health Survey (NFHS-5) and the way forward. J Family Med Prim Care 2024;13:4552–4559.Article PubMed PMC
38. Dandona R, George S, Majumder M, Akbar M, Kumar GA. Stillbirth undercount in the sample registration system and national family health survey, India. Bull World Health Organ 2023;101:191–201.Article PubMed PMC
39. Lever G, Chipeta H, Glanville T, Selinger C. Risk of adverse pregnancy outcomes for women with IBD in an Expert IBD Antenatal Clinic. J Clin Med 2022;11:2919.Article PubMed PMC
40. Suriani R, Ercole E, Niola P, Astegiano M, Sambataro A, Ravizza M. IBD passport: a novel educational model in IBD patients. Dig Liver Dis 2020;52:1067–1068.Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Optimizing disease assessment and care pathways for pregnant women with inflammatory bowel disease
Arshdeep Singh, Harmeet Kaur, Arshia Bhardwaj, Vandana Midha, Ajit Sood
Indian Journal of Gastroenterology.2026;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

The impact of inflammatory bowel disease on women’s health: a cross sectional study in India

DOI: https://doi.org/10.5217/ir.2025.00088

XML Download

Figure

Related articles

The impact of inflammatory bowel disease on women’s health: a cross sectional study in India

Fig. 1. Impact of IBD on menstrual and sexual health and pregnancy. (A) severity of symptoms during menstruation (median value on VAS), (B) disruption of sexual act due to abdominal/pelvic pain, (C) complications during pregnancy, (D) reasons for apprehension about conception. VAS, visual analog scale; IBD, inflammatory bowel disease.

Fig. 2. mpact of IBD on social domain of health (A) self-perceived perception of acceptance in society, (B) the distribution of social impact of chronic conditions in IBD (SICC-IBD) scores, and (C) number of patients responding in affirmation to different questions in the SICC-IBD score. IBD, inflammatory bowel disease.

Fig. 3. The environmental impacts of IBD (A) major challenges faced while making changes to the diet, post-IBD diagnosis, (B) access to IBD medicines in hometown, (C) travel time from home to IBD care facility. IBD, inflammatory bowel disease.

Fig. 4. The multifaceted impact of IBD on women’s health. ASEX, Arizona Sexual Experiences Scale; HPV, human papillomavirus; IBD, inflammatory bowel disease; INR, Indian Rupee; SICC-IBD, social impact of chronic conditions in IBD.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

The impact of inflammatory bowel disease on women’s health: a cross sectional study in India

Demographics	Value
Age (yr)	41.00 (32.00–48.25)
Body mass index (kg/m²)	23.06 (20.07–25.74)
Marital status
Married	167 (82.67)
Unmarried	27 (13.36)
Widow/divorcee	8 (3.96)
Kuppuswamy socioeconomic class
Upper lower	18 (8.91)
Lower middle	99 (49.00)
Upper middle	67 (33.16)
Upper	18 (8.91)
Disease characteristics
Ulcerative colitis	155 (76.73)
Disease extent
Proctitis	45 (29.03)
Left sided colitis	88 (56.77)
Pancolitis	22 (14.19)
Disease activity at enrolment (partial Mayo score)^a
Remission	59 (38.06)
Mild	66 (42.58)
Moderate	22 (14.19)
Severe	8 (5.16)
Crohn’s disease	47(23.26)
Disease classification
Age at diagnosis (yr)
< 17	2 (4.25)
17–40	25 (53.19)
> 40	20 (42.55)
Disease location
Ileal	14 (29.78)
Colonic	14 (29.78)
Ileocolonic	19 (40.42)
Disease behavior
Non stricturing, non-penetrating	33 (70.21)
Stricturing	10 (21.27)
Fistulizing	4 (8.51)
Perianal disease	4 (8.51)
Disease activity at enrolment (HBI)^b
Remission	31 (65.95)
Mild	11 (23.40)
Moderate	5 (10.63)
Extraintestinal manifestations
Peripheral arthritis	42 (20.79)
Axial arthritis	21 (10.39)
Peripheral + axial arthritis	8 (3.96)
Pyoderma gangrenosum	2 (0.99)
Erythema nodosum	2 (0.99)
Primary sclerosing cholangitis	1 (0.49)
Nephrolithiasis	4 (1.98)
Episcleritis	2 (0.99)
Concomitant medications
Oral 5-aminosalicylates	194 (96.04)
Rectal 5-aminosalicylates	98 (48.51)
Corticosteroids
Prednisolone	23 (11.38)
Budesonide	51 (25.24)
Thiopurines	36 (17.82)
Tofacitinib	80 (39.60)
Anti-TNFs	8 (3.96)
Vedolizumab	4 (1.98)
Ustekinumab	3 (1.48)
IBD-related surgery
Small bowel resection	5 (2.47)
Proctocolectomy with IPAA	3 (1.48)
Perianal fistula surgery	3 (1.48)
Comorbid illness
Diabetes mellitus	5 (2.47)
Hypertension	7 (3.46)
Hypothyroidism	15 (7.42)
Celiac disease	3 (1.48)
Family dynamics and family history
Number of siblings	3 (2–4)
Birth order	2 (1–3)
Family history of IBD	8 (3.96)

	UC (n = 155)	CD (n = 47)	P-value	UC active disease (n = 96)	UC in remission (n = 59)	P-value	CD active disease (n = 16)	CD in remission (n = 31)	P-value
Patient and disease characteristics
Age (yr)	39.6 ± 10.8	44.2 ± 13.3	0.020	38.9 ± 10.5	40.9 ± 11.2	0.260	40.6 ± 13.1	46.0 ± 13.2	0.200
Age at diagnosis (yr)	31.1 ± 10.3	37.1 ± 13.4	0.001	30.6 ± 10.1	32.1 ± 10.7	0.390	33.5 ± 12.5	39.0 ± 13.6	0.180
Body mass index (kg/m²)	23.5 ± 4.5	22.3 ± 4.5	0.110	23.2 ± 4.6	23.8 ± 4.2	0.420	20.3 ± 3.3	23.3 ± 4.8	0.040
Total Kuppuswamy score	15.0 (13.0–17.0)	16.0 (13.0–18.0)	0.120	15.0 (13.0–18.0)	15.0 (12.0–16.0)	0.600	15.5 (13.2–17.0)	16.0 (13.0–19.0)	0.680
Disease duration (yr)	5.0 (2.0–12.0)	6.0 (3.0–12.0)	0.350	5.0 (3.0–11.7)	6.0 (3.0–13.0)	0.310	5.5 (1.2–13.0)	4.0 (3.0–11.0)	0.910
Partial Mayo score	2.0 (0.0–4.0)	-	-	3.0 (3.0–5.0)	0.0 (0.0–0.0)	< 0.001	-	-	-
Harvey Bradshaw Index	-	3.0 (2.0–5.0)	-	-	-	-	5.0 (5.0–8.7)	2.0 (1.0–3.0)	< 0.001
Concomitant therapy
5-Aminosalicylates	153 (98.7)	41 (87.2)	< 0.001	95 (98.9)	58 (98.3)	0.720	15 (93.8)	26 (83.9)	0.340
Corticosteroids	56 (36.1)	18 (38.3)	0.780	46 (47.9)	10 (16.9)	< 0.001	8 (50.0)	10 (32.2)	0.240
Thiopurines	21 (13.5)	15 (31.9)	0.004	13 (13.5)	8 (13.5)	0.990	4 (25.0)	11 (35.5)	0.470
Biologics/small molecules	69 (44.5)	26 (55.3)	0.190	43 (44.8)	26 (44.1)	0.930	8 (50.0)	18 (58.1)	0.600
Extraintestinal manifestations
Peripheral arthritis	29 (18.7)	13 (27.7)	0.180	17 (17.7)	12 (20.3)	0.680	5 (31.3)	8 (25.8)	0.690
Axial arthritis	15 (9.7)	6 (12.8)	0.540	13 (13.5)	2 (3.4)	0.040	1 (6.3)	5 (16.1)	0.340
Deep venous thrombosis	3 (1.9)	0	0.330	1 (1.0)	2 (1.0)	0.290	0	0	-
Gall stone	7 (4.5)	7 (14.9)	0.010	4 (4.2)	3 (5.1)	0.800	1 (6.3)	6 (19.4)	0.230
Pyoderma gangrenosum	2 (1.3)	0	0.430	1 (1.0)	1 (1.7)	0.700	0	0 (0.0)	-
Erythema nodosum	1 (0.6)	1 (2.1)	0.360	0	1 (1.7)	0.200	0	1 (3.2)	0.470
Scleritis/episcleritis	0	2 (4.3)	0.010	0	0	-	2 (12.5)	0	0.050
Nephrolithiasis	4 (2.6)	0	0.260	3 (3.1)	1 (1.7)	0.600	0	0	-
Primary sclerosing cholangitis	1 (0.6)	0	0.580	0	1 (1.7)	0.200	0	0	-
Family history of IBD	5 (3.2)	3 (6.4)	0.330	1 (1.0)	4 (6.8)	0.050	1 (6.3)	2 (6.5)	0.970
Evaluation for anemia
Hemoglobin (g/dL)	10.4 ± 1.7	10.2 ± 1.9	0.350	10.5 ± 1.7	10.2 ± 1.8	0.290	9.2 ± 1.6	10.6 ± 1.9	0.020
Anemia present	123 (79.3)	39 (83.0)	0.580	76 (79.2)	47 (79.7)	0.940	16 (100.0)	23 (74.2)	0.030
Iron deficiency anemia	91 (58.7)	24 (51.1)	0.350	56 (58.3)	35 (59.3)	0.900	12 (75.0)	12 (38.7)	0.020
Reproductive health
Age at menarche (yr)	13.1 ± 1.8	13.1 ± 1.6	0.930	13.1 ± 1.8	13.1 ± 1.8	0.860	12.9 ± 1.7	13.2 ± 1.6	0.610
Age at menopause/hysterectomy (yr)^a	43.1 ± 4.1	42.2 ± 5.2	0.460	42.7 ± 4.6	43.7 ± 3.3	0.440	41.2 ± 5.5	42.4 ± 5.2	0.690
Are your periods regular?
Always irregular	8 (5.2)	3 (6.4)	0.750	3 (3.1)	5 (8.5)	0.140	1 (6.3)	2 (6.5)	0.970
Mostly irregular	47 (30.3)	11 (23.4)	0.360	34 (35.4)	13 (22.0)	0.080	5 (31.3)	6 (19.4)	0.360
Mostly regular	56 (36.1)	13 (27.7)	0.290	32 (33.3)	24 (40.7)	0.350	6 (37.5)	7 (22.6)	0.280
Not applicable, post menopausal	44 (28.4)	20 (42.6)	0.070	27 (28.1)	17 (28.8)	0.920	4 (25.0)	16 (51.6)	0.080
Periods worsen IBD activity	34 (21.9)	5 (10.6)	0.090	22 (22.9)	12 (20.3)	0.700	4 (25.0)	1 (3.2)	0.020
Marital status
Married	132 (85.2)	35 (74.5)	0.090	83 (86.5)	49 (83.1)	0.560	10 (62.5)	25 (80.6)	0.180
Unmarried	18 (11.6)	9 (19.1)	0.190	10 (10.4)	8 (13.6)	0.550	5 (31.3)	4 (12.9)	0.130
Widow	3 (1.9)	1 (2.1)	0.930	2 (2.1)	1 (1.7)	0.860	0 (0.0)	1 (3.2)	0.470
Divorced	2 (1.3)	2 (4.3)	0.190	1 (1.0)	1 (1.7)	0.700	1 (6.3)	1 (3.2)	0.620
Age at marriage (yr)	22.6 ± 2.8	21.7 ± 2.6	0.800	22.6 ± 2.7	22.8 ± 2.7	0.760	21.1 ± 2.2	22.0 ± 2.8	0.320
Diagnosis of IBD before marriage	25 (16.1)	3 (6.4)	0.090	17 (17.7)	8 (13.6)	0.500	1 (6.3)	2 (6.5)	0.970
Unmarried, facing difficulty in marriage^b	18 (100.0)	9 (100.0)	0.180	10 (10.4)	8 (13.6)	0.540	5 (31.3)	4 (12.9)	0.130
Ever been pregnant	128 (82.6)	37 (78.7)	0.530	78 (81.3)	50 (84.7)	0.590	10 (62.5)	27 (87.1)	0.050
Advised about contraception by physician	20 (12.9)	4 (8.5)	0.410	14 (14.5)	6 (10.2)	0.430	1 (6.3)	3 (9.7)	0.690
Still births	3 (1.9)	2 (4.2)	0.360	1 (1.0)	2 (3.4)	0.290	0	2 (6.4)	0.300
Spontaneous abortion	26 (16.8)	9 (19.1)	0.720	15 (15.6)	11 (18.6)	0.630	4 (25.0)	5 (16.1)	0.460
Medical termination for unwanted pregnancy	14 (9.0)	5 (10.6)	0.740	6 (6.3)	8 (13.6)	0.120	0	5 (16.1)	0.090
Pregnancy getting terminated due to IBD activity	9 (5.8)	1 (2.1)	0.300	6 (6.3)	3 (5.1)	0.760	0	1 (3.2)	0.470
Concerns about breastfeeding the child while being on IBD medicines	53 (34.2)	12 (25.5)	0.260	37 (38.5)	16 (27.1)	0.140	2 (12.5)	10 (32.3)	0.140
Apprehensive about transmission of disease while breastfeeding	72 (46.5)	24 (51.1)	0.580	48 (50.0)	24 (40.7)	0.260	8 (50.0)	16 (51.6)	0.910
Received advice about cervical cancer screening	2 (1.3)	3 (6.4)	0.050	2 (2.1)	0	0.260	0	3 (9.7)	0.200
Received HPV vaccine	6 (3.9)	2 (4.3)	0.900	4 (4.2)	2 (3.4)	0.800	0	2 (6.5)	0.300
Social health
Total SICC-IBD score	0.5 ± 0.2	0.6 ± 0.2	0.280	0.5 ± 0.1	0.5 ± 0.2	0.270	0.6 ± 0.2	0.6 ± 0.1	0.940
SICC-IBD score
< 0.5	64 (41.3)	17 (36.2)	0.500	38 (39.6)	26 (44.1)	0.580	6 (37.5)	11 (35.5)	0.890
≥ 0.5	91 (58.7)	30 (63.8)		58 (60.4)	33 (55.9)		10 (62.5)	20 (64.5)
Mental health
Total score on Perceived Stress Scale	21.0 (18.0–23.0)	19.0 (18.0–22.0)	0.020	21.0 (19.0–24.0)	20.0 (18.0–22.0)	0.050	20.0 (19.0–22.0)	18.0 (18.0–22.0)	0.190
Perceived Stress Scale score
14–26	146 (94.2)	46 (97.8)	0.300	89 (92.7)	57 (96.6)	0.310	15 (37.5)	31 (100.0)	0.160
≥ 27	8 (5.2)	1 (2.1)	0.370	6 (6.2)	2 (3.4)	0.430	1 (6.2)	0	0.160
Total anxiety score on HADS	14.0 (9.0–17.0)	14.0 (8.0–17.0)	0.690	14.0 (12.0–18.0)	13.0 (8.0–14.0)	0.010	16.5 (10.2–21.0)	13.0 (8.0–14.0)	0.040
Anxiety score on HADS > 10	113 (72.9)	29 (61.7)	0.140	76 (79.2)	37 (62.7)	0.020	12 (75.0)	17 (54.8)	0.180
Total depression score	14.0 (11.0–16.0)	14.0 (10.0–17.0)	0.900	14.0 (11.0–17.0]	13.0 (10.0–15.0)	0.740	16.5 (14.0–21.0)	14.0 (9.0–15.0)	0.040
Depression score on HADS > 10	117 (75.5)	35 (74.5)	0.880	75 (78.1)	42 (71.2)	0.330	13 (81.2)	22 (70.9)	0.440
Sexual health
Total Score ASEX^c	15.0 (15.0–20.0)	15.0 (15.0–18.0)	0.650	15.0 (15.0–20.0)	15.0 (15.0–20.0)	0.750	18.0 (15.0–25.0)	15.0 (15.0–18.0)	0.370
Sexual dysfunction (ASEX)	107 (69.0)	30 (63.8)	0.500	69 (71.9)	38 (64.4)	0.330	10 (62.5)	20 (64.5)	0.890

Table 1. Baseline Characteristics (n=202)

Values are presented as median (interquartile range) or number (%).

Partial Mayo Score (PMS): clinical remission (PMS 0-1), mild (PMS 2-4), moderate (PMS 5-7), severe (PMS >7).

HBI: clinical remission (HBI <5), mild (HBI 5–7), moderate (HBI 8–15), severe (HBI >15).

TNF, tumor necrosis factor; IBD, inflammatory bowel disease; IPAA, ileal pouch anal anastomosis; HBI, Harvey Bradshaw Index.

Table 2. Impact of Disease Type and Disease Activity on Key Domains of Health

Values are presented as mean±standard deviation, median (interquartile range), or number (%).

A total of 44 women with UC and 20 women with CD were either postmenopausal or had undergone hysterectomy.

The number of unmarried women was 18 in the UC group and 9 in the CD group.

Sexual activity was reported by 131 women with UC and 34 women with CD.